Literature DB >> 35482756

Drug therapy problems and predicting factors among ambulatory epileptic patients in Jimma Medical Center, Southwest Ethiopia.

Yadeta Babu Beyene1, Fekede Bekele Daba2, Kabaye Kumela Goro2, Birbirsa Sefera Senbeta1.   

Abstract

BACKGROUND: The care of epileptic patients is complicated by the cognitive adverse effect of the drug, disease, pharmacokinetics, and pharmacodynamics properties of antiepileptic drugs which in turn intensify the risk of drug therapy problems among epileptic patients.
OBJECTIVE: To assess drug therapy problems and predicting factors among ambulatory epileptic patients at Jimma University Medical Center, Southwest Ethiopia, from September 2020 to May 2021.
METHODOLOGY: A hospital-based prospective observational study was conducted. A semi-structured questionnaire was used to collect data from patients as well as from charts. Drug therapy problems were identified using Cipolle's, Morley, and Strand drug therapy problem identification and classification method. Data were entered into Epi data manager version 4.6 and exported to statistical software package for social science version 23.0 for analysis. Multiplestepwise backward logistic regression analysis was carried out to identify predictors of drug therapy problems. The 95% CI was used to show an association between the dependent and independent variables. P-value < 0.05 was considered as statistically significant.
RESULTS: Of the total 320 epileptic patients 224(70.0%) patients had at least one drug therapy problem. A total of 395 drug therapy problems were identified among two hundred twenty-four patients with an average of 1.2 drug therapy problems per patient. The frequently identified drug therapy problems were non-compliance 115(29.11), adverse drug reaction 110(27.84%), and dose too low 103(26%). Getting of a drug by purchasing [AOR = 4.6,95%CI:(2.05-10.7)], poorly involvement of the patients in therapeutic decision making [AOR = 3.02,95%CI:(1.5-6.06)], the number of medications ≥ two [AOR = 5.3,95%CI:(1.2-22.9)] and having had uncontrolled seizure [AOR = 10.9,95%CI:(4.9-24.2)] were independent predictors of drug therapy problems.
CONCLUSIONS: Drug therapy problems were common among epileptic patients in the study area. Patients who were getting their drugs by purchasing, poorly involved in therapeutic decision making, having had an uncontrolled seizure, and taking two and above drugs were more likely to experience drug therapy problems. Therefore, due attention should be given to patients with the aforementioned problems to decrease the occurrence of drug therapy problems and improve overall outcomes among epileptic patients.

Entities:  

Mesh:

Year:  2022        PMID: 35482756      PMCID: PMC9049505          DOI: 10.1371/journal.pone.0267673

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.752


1. Background

Epilepsy is a chronic neurological disorder characterized by recurrent seizure attacks [1]. It accounts for 0.5% of the global burden of disease and has significant economic implications in terms of premature death, health-care-related needs, and lost work productivity [2]. In 2017 International League against Epilepsy (ILAE) classify epilepsy as focal seizures, generalized seizures, and unclassified seizures [3]. Epilepsy is a global public health problem affecting more than 70 million people worldwide, and more than 85% of the global burden of epilepsy occurs in developing countries [4]. In Africa, epilepsy affected about 10 million people and Ethiopia is one of the highly affected countries with an estimated prevalence of 14.2/1000 population and an annual incidence of 64 per 100,000 population [5]. Antiepileptic drugs (AEDs) are indicated for patients who have had one or more epileptic seizures. The choice of medication for the treatment of epilepsy is varied depending on the type, severity, and frequency of epileptic seizures [6, 7]. The majority of epileptic seizures are controlled with the optimal use of the currently available AEDs. However, about one-third remained uncontrolled despite optimal therapy [8, 9] Drug therapy problem (DTP) is common in epileptic patients because of the complexity of AEDs and the disease itself. The complexity of medical problems and comedications for patients requiring AEDs can result in an increased likelihood of drug interactions and drug toxicity which in turn intensify the risk of having drug therapy problems and negatively affects the seizure control status of the patients [10]. DTP is an event related to medication therapy that actually or potentially interferes with the desired health outcome [11]. DTP can occur at various stages of the medication use processes, including while prescribing, transcribing, dispensing, and when the patients use drug therapy [12]. DTPs are categorized into seven major classes composed of, unnecessary drug therapy, need additional drug therapy, ineffective drug therapy, dosage too low, dosage too high, adverse drug reaction (ADR), and non-compliance [12]. Generally, DTP is one of the major public health problems and has been significantly increased over the past few years. Despite more than 50% of DTP is being avoidable 5–10% of hospital admission were due to DTP [13]. The World Health Organization (WHO) estimates that globally “more than half of all medicines are prescribed, dispensed, or sold inappropriately and that half of all patients fail to take their medicines correctly [14, 15]. In the US alone it is estimated that 100,000 deaths occur annually due to drug therapy problems and costing approximately $201.4 billion in direct medical costs per year [16]. DTPs in epileptic patients is among major factors that affect the outcome of therapy and the safety of medical care. In epileptic patients, the frequency of DTP has been reported to be as high as 70% to 90.38%, [17, 18]. Disregard to such high-frequency previous studies done in Ethiopia among epileptic patients was primarily focused on the assessment of adherence, but there is only limited study done on the prevalence of drug therapy problem, type of drug therapy problem, and predicting factors of drug therapy problems among epileptic patients. Consequently, this study aimed at assessing drug therapy problems and its predicting factors among epileptic patients at the ambulatory clinic of Jimma University medical center and providing clinical pharmacist intervention for identified drug therapy problems.

2. Methods and materials

2.1 Study design and study setting

A hospital-based prospective observational study was conducted from September 2020 to May 2021 at the ambulatory care clinic in JUMC, Oromia, Ethiopia. JUMC is located in Jimma town, 352 km Southwest of Addis Ababa, Ethiopia. It is among the largest teaching institution in Ethiopia and is the only teaching and referral hospital in the southwestern part of the country and provides services for the catchment population of about 15 million people.

2.2 Study population and data collection procedure

Adult epileptic patients with complete medical records and regular follow-up for minimum of six months were included in the study. Patients were included into the study during their appointment for medication refilling. Patients who were, seriously ill to complete the interview, unwilling to give consent, and had incomplete medical records were excluded from the study. A sample of 320 was calculated using a single population proportion formula by using the following assumptions: Z = 1.96, P = 70.4% proportion of DTP at TASH [17], 95% confidence level, 5% margin of error. Patients were interviewed during their follow-up period for the medication refilling and the medical chart was retrieved using the checklist for retrieval. Interview questions included socio-demographics, behavioral-related factors, patient involvement in therapeutic decision making, and noncompliance assessment. The respective patient’s medical and medication records were reviewed. Three clinical pharmacists (1st-degree holders) were involved in the data collection process. One day training and orientation were given to the data collectors before the beginning of the study.

2.3 Drug therapy problems identification and classification

In the current study, DTPs were classified according to Cipolle, Morley, and Strand’s DTPs classification method [12]. The DTPs were identified by an independent team of clinical pharmacists by using the data collected from the patients through interviewing and medical records through reviewing. The prescribed drugs were evaluated against different international and national guidelines such as National Institute for Health and Care Excellence (NICE), American Academy of Neurology 2018 (AAN), ILAE guideline, Dipro-pharmacotherapy 11th edition, Epilepsy Prescriber’s Guide 3rd edition, 2020 Ethiopian standard treatment guideline, UpToDate 2018 and Lexicomp version 1.1 drug interaction checker. The identified DTP were classified as, need additional drug therapy, too low dosage, ineffective therapy, too high dosage, ADR, and non-compliance.

2.4 Intervention development and implementation

Pharmacist’s interventions were provided for individual patients based on the types of identified DTPs. If the identified DTP was non-compliance, counseling was provided for the patients on spot. For other types of DTP requiring the involvement of physicians, the clinical pharmacists were communicated with the responsible physician and provided recommendations with the ultimate goal of optimizing medication therapy by using the aforementioned reference materials on the patient’s appointment day for a refill.

2.5 Data quality assurance

Pretest was done on sixteen patients, (5%) of the study participants to ensure the appropriateness of the data collection instruments, and the modifications were undertaken based on the information from pre-test. The data collection processes were supervised and the collected data were checked by the principal investigator (PI) on the daily basis.

2.6 Statistical analysis

The collected data were compiled, cleared, coded, and checked for completeness and accuracy before entering into software. Epi data manager version 4.6 and SPSS version 23.0 were used for data entry and analyses respectively. All statistical tests were performed using SPSS version 23.0. Descriptive statistics were computed as frequency, mean and standard deviation (SD). Multicollinearity was checked among independent variables and no collinearity was found. To determine the association between dependent and independent variables, Univariable logistic regression analysis was done. The independent variables with a p-value <0.25 were included in a final model (multivariate) to identify predictors of DTPs. A p-value of <0.05 was considered statistically significant in all analyses. The Odds ratio with a 95% confidence interval (CI) was used to measure the strength of association between independent and dependent variables. The outputs of processed data were presented by tables and figures.

2.7 Ethical consideration

The approval letter for this study was taken from the institutional review board (IRB) of Jimma University, College of Health Sciences. The objective of the study was explained and written informed consent was obtained from study participants. For the matter of patient confidentiality, the name and address of the patients were not included in the data collection tools.

2.8 Operational definitions

Controlled seizure: is free of seizure episode for the minimum of the last two years. Uncontrolled seizure: Patients experienced at least one seizure episode in the last two years. Unclassified seizure: Documented diagnosis as epilepsy disorder without any classification. DTP: DTP is an event related to medication therapy that actually or potentially interferes with the desired health outcome [11]. ADRs: Any noxious, unintended, and undesired effect experienced by the patient which was associated with the drug. Co-morbidity: Medical condition/s other than epilepsy. Pharmacist intervention: A recommendation suggested by the clinical pharmacist for changing the patients’ therapeutic management. Accepted: When the suggested problems were recognized and accepted. Drug interaction: Presence of significant drug-drug interaction. Patient involvement in drug therapy decision: This is the degree of patient involvement in the making of decision about their drug therapy. It was measured using a 2-item 5-point Likert scale using a self-reported questionnaire about patient involvement in therapeutic decision making. The respondents indicated their degree of involvement ranging from 1 = never to 5 = all times. Accordingly, patients were said to be actively involved if the average score was above the mid-point (>5) otherwise poorly involved [19]. The identified DTPs were categorized based on Cipolle’s method [12] as follows: Need for additional drug therapy: was considered when the medical condition requires additional drug therapy to achieve synergistic or additive effects. Ineffective drug therapy: was considered when the drug is used for a medical condition that is refractory to the drug product. Dosage too high: was considered when the dose is too high, the duration of drug therapy is too long and the drug interaction occurs that could result in a toxic reaction. Too low dose: was identified when the prescribed dose was too low to produce the intended response, and when the amount of active drugs available were reduced due to drug interaction. Adverse drug reaction: was considered when the drug causes an undesirable reaction that was not dose-related, a safer drug product is required due to risk factor, the drug product is contraindicated due to risk factor. Noncompliance: was considered if a patient fails to take medications appropriately due to one of the following reasons, the difficulty of understanding the instructions, preferring not to take medication, expensiveness of drug product, forgetfulness, and unavailability of medication.

3. Results

3.1 Socio-demographic and behavioral related characteristics

A total of 320 epileptic patients were included in the study. The study subject’s mean age was 29.9 ±11.2 SD and about half of them, 149(46.6%) were young adults within the age category of (18–25 years). More than half of the study subjects were male 176(55%) and 170(53%) of study participants were from rural areas. Regarding monthly income 287(89.7%) of study, subjects have no regular income. Among the study participants, 230 (71.9%) were educated, and greater than half, 188 (58.8%) of the study participants were getting their medication freely. From study participants, only 64(20%) were social drug users (Table 1).
Table 1

Socio-demographic and behavioral related characteristics of epileptic patients attending the ambulatory clinic of JMC, 2021.

CharacteristicsFrequency (n)Percentage (%)
Mean (±SD) age29.9 ±11.2
Age in years
18–2514946.6
26–4413241.3
≥453912.2
Gender
Male17655
Female14445
Residency
Urban15046.1
Rural17053.1
Monthly income
No regular income28789.7
Regular income3310.31
Educational status
Un educated9028.1
Educated23071.9
Occupation
Farmer8727.2
Student6018.8
Daily laborer299.1
Employed226.9
Merchant144.4
Housewife3611.3
Jobless7222.5
Religion
Orthodox7724.1
Muslim21868.1
Protestant206.3
Catholic51.6
Living condition
Living alone226.9
With family29893.1
How to get medication
Free18858.75
Payment13241.25
Social drug-using status
Yes6420
No25680
Patient involvement
Actively involved11736.56
Poorly involved20363.43

3.2 Clinical characteristics of the study participants

From the study participants, 221 (69.1%) were diagnosed with generalized tonic-clonic seizure(GTC). Hundred sixty-two (50.6%) of the patients had a follow-up duration lasting >10 years and half of the study participants 168(52.5%) had controlled seizure. Regarding the comorbid medical condition, 69(21.6%) of participants had comorbidity and frequently reported comorbid medical conditions were dyspepsia 19(5.9%) and hypertension 15(4.6%) (Table 2).
Table 2

Clinical characteristics of epileptic patients attending ambulatory clinic of JMC, 2021.

Clinical characteristicsFrequency (n)Percentage (%)
Types of seizure
GTC22169.1
Focal257.8
Unclassified*7423.1
Follow-up duration
1–5 years8025
6–10 years7824.4
>10 years16250.6
Seizure control status
Controlled16852.5
Uncontrolled15247.5
Comorbidity
Yes6921.6
No25178.4
Comorbid condition
Dyspepsia195.9
Hypertension154.6
Schizophrenia72.2
PNP51.5
RVI41.3
DM41.3
Hemorrhoid41.3
Back pain30.9
Stroke30.9
Othersa51.5

PNP: Peripheral neuropathy, RVI: Retroviral Infection, DM: Diabetic Mellitus, GTC: Generalized tonic-clonic, Unclassified*: documented diagnosis as epilepsy disorder without any classification, Othersa: Ischemic heart disease, Sexual dysfunction, Tinea pedis, Migraine headache.

PNP: Peripheral neuropathy, RVI: Retroviral Infection, DM: Diabetic Mellitus, GTC: Generalized tonic-clonic, Unclassified*: documented diagnosis as epilepsy disorder without any classification, Othersa: Ischemic heart disease, Sexual dysfunction, Tinea pedis, Migraine headache.

3.3. Antiepileptic drug uses pattern among the study participants

A total of 494 AEDs were prescribed over the study period with an average of 1.54 ± 0.5 SD AEDs per patient. Half of the study participants, 162(50.6%) were on a single therapy regimen. Phenobarbital was the most frequently prescribed drug as monotherapy and combination therapy with phenytoin,117(36.5%) and 107 (33.4%), respectively. Regarding the total number of drugs only 50(15.6%) of participants were taking three and above drugs (Table 3).
Table 3

Medication use pattern of epileptic patients attending ambulatory clinic of JUMC, 2021.

VariablesFrequency (n)Percentage (%)
Number of AED
One16250.6
Two14244.3
Three165
AED use pattern
PB11736.5
PHT3912.2
VPA41.3
CBZ20.6
PB+PHT10733.4
PB+CBZ257.8
PB+VPA30.9
PHT+CBZ41.3
PHT+VPA30.9
PB+PHT+CBZ113.4
PB+PHT+VPA30.9
PHT+CBZ+VPA20.6
Total drugs per patient
One drug13742.8
Two drugs13341.56
Three drugs &above5015.6

PHB: phenobarbital, PHT: phenytoin, CBZ: carbamazepine, VPA: Valproic acid.

PHB: phenobarbital, PHT: phenytoin, CBZ: carbamazepine, VPA: Valproic acid.

3.4 Types, prevalence, and cause of drug therapy problems

From a total of 320 patients, 224 patients experienced DTPs, with an overall prevalence of 70%. The most frequent DTPs were noncompliance 115(29.1%), ADR 110(27.8%), and too low dosage 103(26%) (Table 4). From 224 patients who had experienced DTPs, about half of the patients 110(49.1%) had one DTP, 80 (35.7%) patients had two DTPs and 34(15.2%) had three and above DTPs. The average number of DTP per patient was 1.2 (Fig 1).
Table 4

Types and cause of DTP among epileptic patients at the ambulatory clinic of JMC, 2021.

DTP category and causesProportion of DTP, n = 395
Noncompliance 115(29.1)
Does not understand the instruction2(1.7)
Prefer not to take the medication11(9.6)
The drug product is too expensive for the patient33(28.7)
Forgets to take medication39(33.9)
The drug product is not available for the patient30(26.1)
ADR 110(27.8)
The drug product causes an undesirable reaction that is not dose-related97(88.2)
A safer drug product is required due to risk factors7(6.4)
The drug product is contraindicated due to risk factors6(5.4)
Too low dosage 103(26)
The dose is too low to produce the desired response64(62.1)
A drug interaction reduces the amount of active drugs available39(37.8)
Too high dosage 55(13.9)
The dose is too high44(80)
The duration of drug therapy is long for a given condition6(10.9)
Drug interaction 5(9)
Additional drug therapy 9(2.2)
To attain synergistic effect or additive effect9(100)
Ineffective drug therapy 3(0.76)
The medical condition is refractory to the drug3(100)
Fig 1

Number of drug therapy problems among epileptic patients attending the ambulatory clinic of JMC, 2021.

3.5 The types and status of interventions carried out

A total of 358 (90.6%) interventions were undertaken by clinical pharmacists. The remaining (4.3%) were solved by the other health care team and (5.1%) were not intervened due to loss of patient from follow-up. Counseling of the patients (58.94%) and recommendation for dosage adjustment (30.97%) were the most common intervention provided by clinical pharmacists during the study period. From the total intervention given, 254(70.94%) were accepted fully with an acceptance rate of 71% (Table 5).
Table 5

Types and status of intervention provided for epileptic patients attending ambulatory clinic of JMC, 2021.

Types and status of interventionFrequency (n)Percentage (%)
Counseling on adherence and ADR21158.94
Increasing dosage6117
Decreasing dosage5013.97
Addition of medication71.96
Switching of medication277.54
Discontinuation of medication20.56
Intervention is fully accepted25471
Intervention is accepted with modification4312.01
Intervention is not accepted6117.04

3.6 Predicting factors of drug therapy problems

Depending on the outputs of multivariable logistic regression model getting of medications by purchasing (AOR = 4.6,95%CI = 2.05–10.7), Poorly involvement of the patient in therapeutic decision making (AOR = 3.02,95%CI = 1.5–6.06), Having had an uncontrolled seizure (AOR = 10.9,95%CI = 4.9–24.2), and taking of two and above drugs (AOR = 5.3,95%CI = 1.2–22.9) were independent predicting factors of DTPs (Table 6).
Table 6

Bivariate and multivariate analysis of factors associated with DTPs among epileptic patients attending ambulatory clinic of JMC, 2021.

VariablesDTPBivariate analysisMultivariate analysis
Age in yearYesNoCORP-valueAORP-value
18–2597(43.3)52(54.17)11
26–4498(43.8)34(35.4)1.54(0.92–2.5)0.0981.46(0.68–3.1)0.323
≥4528(12.5)11(11.45)1.36(0.63–2.96)0.4321.15(0.39–3.3)0.793
Residency
Urban111(49.6)39(40.6)11
Rural112(50.4)58(60.4)0.67(0.41–1.1)0.1160.98(0.48–1.9)0.98
Social drug use status
Yes42220.77(0.43–1.39)0.394---------------------------------------
No182741
Medication fee
Free103(45.9)85(88.5)11
Payment120(53.5)12(12.5)8.2(4.2–15)<0.0014.6(2.05–10.7)<0.001
Patient involvement
Actively involved56(25)61(63.5)11
Poorly involved167(74.5)36(37.5)3.3(2–5.5)<0.0013.02(1.5–6.06)0.002
Type of seizure
GTC158(70.5)63(65.6)1
Focal19(8.4)6(6.25)1.2(0.48–3.3)0.6350.47(0.12–1.9)0.293
Unclassified46(20.5)28(29.1)0.65(0.37–1.13)0.1340.41(0.11–1.7)0.24
Follow up duration
1–5 years49(21.8)32(33.33)11
6–10 years56(25)22(22.9)1.7(0.85–3.2)0.1341.74(0.68–4.4)0.244
>10 years118(52.6)43(44.8)1.8(1.02–3.15)0.0431.6(0.71–3.78)0.243
Seizure control status
Controlled82(36.6)86(89.58)11
Uncontrolled141(62.9)11(11.45)13.4(6.7–26.6)<0.00110.9(4.9–24.2)<0.001
Quantity of AED
One96(42.85)64(66.7)1
Two and above127(56.7)33(34.37)2.5(1.5–4.2)<0.0010.29(0.06–1.4)0.129
Comorbidity
Yes61(27.23)8(8.3)4.2(1.9–9.1)<0.0011.73(0.61–4.8)0.297
No162(72.3)89(92.7)11
Total drugs
One75(33.48)62(64.58)11
Two100(44.6)33(34.37)2.5(1.5–4.2)0.0015.3(1.2–22.9)0.024
Three and above48(21.42)2(2.08)19.8(4.6–24)<0.00131(3.8–50)0.001

4. Discussion

In clinical practice, a wide range of DTPs may arise [20]. The prevalence of DTPs among epileptic patients varied from study to study. In this study setting the prevalence of DTPs was found to be 70%, which was in line with the study conducted in TASH (70%) [17] and in Bangalore (76.9%) [21], but higher than the study reported from China (48.1%) [22] and India (13%) [23]. This variation might be due to the variation of clinical characteristics of study participants, availability of trained prescribers, and methods of DTP identification and classification. In the current study, the frequently identified DTP was noncompliance 115(36%) with the main reasons of forgetfulness followed by the expensiveness of the drug products. This finding was comparable with the other study done in Ethiopia (34.1%) [24], Saud Arabia (38%) [25], India (37%) [26], and China (33.3%) [27]. However, it was higher than the study conducted in Paris [28] and USA [29] where 21% and 26% of study participants were noncompliant to AEDs respectively. The probable reasons for this discrepancy could be due to differences in economic status, availability of drugs, belief, education, and physicians’ approach to their patients that could bring differences in patients’ attitudes towards medications. Adverse effects of AEDs are major causes of iatrogenic disease and make a significant contributionto reduced quality of life in individuals with epilepsy. Overall, the incidence of patients experienced ADR in this study was found to be 110(34.37%) which was in line with the finding reported from Malaysia (31%) [30], India (30%) [26], and Ethiopia (37%) [24]. This showed that adverse effects associated with AED were common among epileptic patients. Therefore, its assessment should be routine practice at each visit. In this study, inappropriate dosing (dose too low and dose too high) accounted for 40% of allDTPs. This finding was two times higher than the study reported from Bishoftu general hospital(17.6%) [31] and Thailand (19.47%) [18]. This variation could be due to differences in the DTP classification method used, less frequent use of combination therapy, and short duration of study period by the previous study. In this finding, 41.25% of study participants were getting their medication through purchasing and DTPs were more likely to happen among this group of patients than those patients who were getting their medications freely. This finding was in agreement with a study done in Kenya [32] and Dilla University Referral Hospital [33], where a similar group of patients had three times and two times chance of developing DTP respectively. The possible explanations for why these groups of patients were more prone to have DTP could be due to the shortage of the resources they were not compliant to their medications and follow-up schedule which increases the risk of having DTPs among these groups of patients. The other independent predicting factor for the occurrence of DTP among study participants was having had an uncontrolled seizure. In this finding, 47.5% of the study participants had an uncontrolled seizure and DTPs were more common in this group of patients than patients with controlled seizures. This finding was in line with former studies from Brazil [34], Indonesia [35], and Bangladesh [36], where DTP was highly common among a group of patients with an uncontrolled seizure. This could be due to patients with uncontrolled seizures may have a wrong attitude about their medication’s effectiveness and may refuse to take it. Therefore, further recognition and support should be given to patients with uncontrolled seizures since they are more likely to be more anxious and may have wrong beliefs about their medications. A number of drugs were one of the other independent predicting factors for DTPs. Accordingly, those patients who were taking two and above medications were more prone to have DTPs than patients who were taking less than two medications. This finding was augmented by the study reported from Mekelle University [37], Saud Arabia [25], and Nigeria [38], where multiple therapies significantly influence the occurrence of DTPs. The possible reason might be since, multiple therapies are attributed to the complexity of a treatment regimen involving a larger number of pills that need to be taken at different time intervals, which increases the likelihood of missed doses, drug interaction, and ADR. Hence health care professionals should give due attention to those patients to decrease the likelihood of DTP occurrence and improve treatment outcomes among epileptic patients. Active participation of patients in their care process is important to provide quality of pharmaceutical care service and in minimizing problems associated with the treatment [12]. In this study patients who were poorly involved in their drug therapy decision making were more likely to have DTPs than those who were actively involved in decision-making. This finding was supported by the study conducted in other chronic medical conditions at JUMC, in which poorly involved patients were four times more likely to have DTPs than actively involved patients [19]. The possible explanations for this could be poorly involved patients in therapeutic decision making may have a wrong belief about their disease and medication which make them nonadherent to their AED. Therefore, to minimize the occurrence of DTP, the involvement of patients in decision making needs to be part of the management process in epileptic patients. In the current study, a total of 358 clinical pharmacist interventions were provided at the level of patients and physicians with an acceptance rate of 71%. This finding was supplemented by another study from Goba Referral Hospital, in which (72.6%) interventions were accepted [39]. In this finding counseling of the patients (59%) and dosage change (31%) were the top two clinical pharmacist interventions provided for epileptic patients during the study period. This showed that clinical pharmacists can prevent and resolve DTPs through effective communications and collaboration with other health care professionals and patients.

5. Conclusion

Drug-related problems were prevalent among ambulatory epileptic patients on follow-up during the study period. The most frequently identified DTPs were non-compliance, ADR, and inappropriate dosage. The finding also revealed that source of medication fee, number of drugs, patient involvement in therapeutic decision making, and seizure control status were independent predicting factors of DTPs. Regarding the intervention given, counseling of patients and dosage adjustments were the top two clinical pharmacist’s interventions provided with an overall acceptance rate of 71%. This highlights the role of clinical pharmacists in optimizing therapy among epileptic patients. (DOCX) Click here for additional data file. (SAV) Click here for additional data file.
  24 in total

Review 1.  Systemic review on drug related hospital admissions - A pubmed based search.

Authors:  Kolli Nivya; Vempati Sri Sai Kiran; Nandita Ragoo; B Jayaprakash; M Sonal Sekhar
Journal:  Saudi Pharm J       Date:  2013-05-30       Impact factor: 4.330

2.  Adherence to medication among outpatient adolescents with epilepsy.

Authors:  Wael M Gabr; Mohamed E E Shams
Journal:  Saudi Pharm J       Date:  2014-05-26       Impact factor: 4.330

3.  Adherence to treatment and influencing factors in a sample of Chinese epilepsy patients.

Authors:  Jianming Liu; Zhiliang Liu; Hu Ding; Xiaohong Yang
Journal:  Epileptic Disord       Date:  2013-09       Impact factor: 1.819

4.  Medication Belief and Adherence among Patients with Epilepsy.

Authors:  Yirga Legesse Niriayo; Abraham Mamo; Kidu Gidey; Gebre Teklemariam Demoz
Journal:  Behav Neurol       Date:  2019-04-23       Impact factor: 3.342

Review 5.  Clinically relevant drug interactions with antiepileptic drugs.

Authors:  Emilio Perucca
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

6.  The association of psychosocial variables with adherence to antiepileptic drugs in patients with temporal lobe epilepsy.

Authors:  Shan Wang; Cong Chen; Bo Jin; Linglin Yang; Yao Ding; Yi Guo; Yi Chen; Shuang Wang; Meiping Ding
Journal:  Epilepsy Behav       Date:  2017-11-05       Impact factor: 2.937

7.  Risk factors associated with the epilepsy treatment gap in Kilifi, Kenya: a cross-sectional study.

Authors:  Caroline K Mbuba; Anthony K Ngugi; Greg Fegan; Fredrick Ibinda; Simon N Muchohi; Christopher Nyundo; Rachael Odhiambo; Tansy Edwards; Peter Odermatt; Julie A Carter; Charles R Newton
Journal:  Lancet Neurol       Date:  2012-07-06       Impact factor: 44.182

8.  Drug therapy problems and treatment satisfaction among ambulatory patients with epilepsy in a specialized hospital in Ethiopia.

Authors:  Beshir Bedru Nasir; Alemseged Beyene Berha; Meron Awraris Gebrewold; Yared Mamushet Yifru; Ephrem Engidawork; Minyahil Alebachew Woldu
Journal:  PLoS One       Date:  2020-01-03       Impact factor: 3.240

9.  Antiepileptic drug utilization in Bangladesh: experience from Dhaka Medical College Hospital.

Authors:  Mansur Habib; Sharif Uddin Khan; Azhahul Hoque; Badrul Alam Mondal; A T M Hasibul Hasan; Rajib Nayan Chowdhury; Badrul Haque; Kazi Mohibur Rahman; Ahmed Hossain Chowdhury; Swapon Kumar Ghose; Quazi Deen Mohammad
Journal:  BMC Res Notes       Date:  2013-11-18

10.  Drug therapy problems and contributing factors in the management of heart failure patients in Jimma University Specialized Hospital, Southwest Ethiopia.

Authors:  Yirga Legesse Niriayo; Kabaye Kumela; Tesfaye Dessale Kassa; Mulugeta Tarekegn Angamo
Journal:  PLoS One       Date:  2018-10-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.